Pay in 4 interest-free payments of $6.24 Learn more
Ships within 48 hours · Estimated delivery Aug 16 - Aug 21
Gylfadottir SS, Christensen DH, Nicolaisen SK, et al
The Drug Resistance Crisis Why New Options Matter Why We Urgently Need New Gonorrhea Medication Neisseria gonorrhoeae has earned its reputation as a superbug by systematically developing resistance to every antibiotic class introduced over the past century, making the December 2025 approval of zoliflodacin and gepotidacin a critical turning point in the battle against drug resistant gonorrhea. The Antibiotic Resistance Timeline 1940s: Penicillin became the first effective gonorrhea cure, providing near-100% success rates for two decades before widespread resistance emerged. 1970s-1980s: As penicillin resistance spread globally, healthcare providers shifted to tetracyclines and spectinomycin, only to see Neisseria gonorrhoeae treatment options narrow again within years. 1990s-2007: Fluoroquinolones like ciprofloxacin offered hope as oral gonorrhea antibiotics, but the CDC discontinued fluoroquinolone recommendations in 2007 after surveillance data revealed alarming resistance rates approaching 100% in some regions. 2010-present: Ceftriaxone injections combined with azithromycin became the last-resort standard for gonorrhea treatment, leaving virtually no backup options when resistance develops. The World Health Organization designated Neisseria gonorrhoeae as a high-priority pathogen in 2017 due to multidrug resistance affecting penicillin, tetracyclines, macrolides, sulphonamides, quinolones, and now emerging resistance to extended-spectrum cephalosporins
Addressing Bottlenecks When Progress Stalls Rather than pushing the KLOW dose higher, identify the bottleneck and address it with the appropriate solution: Weak results or lack of visible progress Lifestyle factors: adequate protein, vitamin C, copper-zinc balance, and sleep Low-potency vial: KLOW purity and mass
Bacteriostatic water is not the correct vehicle for every compound or experimental system
Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians
